Entest Biomedical, Inc. Provides Overview of Immuno-Therapeutic Canine Cancer Vaccine Safety Study

SAN DIEGO, CA--(Marketwire - November 30, 2010) - Entest BioMedical Inc. (OTCBB: ENTB) provided an overview of its near term safety study on ImenVax™, the Company’s immuno-therapeutic cancer vaccine for dogs. As previously announced, the Company’s contract research organization’s animal safety committee has approved the protocols necessary to begin the safety study.

Entest BioMedical’s Chairman & CEO David Koos made the following observations regarding the ImenVax™ Safety Study: “Entest views this safety study as paving the way for ImenVax™ to be used by veterinarians for treating dogs with oral melanoma, one of the most common forms of cancer in dogs. We believe this study will not only show ImenVax™ is safe for use in dogs, it will also provide data supporting its efficacy in treating cancer in dogs.”

“One anticipated benefit from this study is potentially identifying enhancements to ImenVax™ that could be incorporated in subsequent versions of the cancer vaccine. We expect to store cancer specimens for future use in immuno-therapeutic research as we expand the ImenVax™ cancer vaccine model. Such expansion to the model potentially impacts types of cancers treated and the level of robustness among the cancer vaccines available,” noted Mr. Koos.

An Entest spokesperson stated the Company expects to start the ImenVax™ Safety Study by the end of the year. The study should take between 6 to 9 months to complete. Once completed, the Company anticipates making ImenVax™ available to veterinarians for treating dogs with oral melanoma.

About Entest BioMedical Inc.:

Entest BioMedical Inc. (OTCBB: ENTB) is a developer of veterinary medicines that harness the animal’s own reparative / immunological mechanisms. The company’s products include an immuno-therapeutic cancer vaccine for canines (ImenVax™). The company’s immuno-therapeutic cancer vaccine utilizes an encapsulation device as the vaccine delivery system and requires a simple implant procedure.

Disclaimer

This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.